Synthetic lethality from the combination of a histone methyltransferase, SUV39H2 inhibitor, and a poly (ADP-ribose) polymerase inhibitor for uterine leiomyosarcoma [RNA-Seq]
RNA-seq (gene expression) · human · 2 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 2 samples
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Synthetic lethality from the combination of a histone methyltransferase SUV39H2 inhibitor and a poly (ADP-ribose) polymerase inhibitor for uterine leiomyosarcomaBMC cancer · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE297689_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1265694 and SRA study SRP586614. Searching any of these in the dataset finder brings you back here.
The sample list for this study is not cached yet. Press Load samples and it will be fetched from NCBI.
+ 2 more — browse all 2 samples with per-sample file links →
- GSE282741 Menin inhibitor DS-1594b drives differentiation and induces synergistic lethality in combination with Venetoclax in acute myeloid leukemia cells with rearranged MLL1 and NPM1 mutations 36 samples shares combination, lethality
- GSE272626 ALS molecular subtypes are a combination of cellular and pathological features learned by deep multiomics classifiers (postmortem spinal cord) 266 samples shares combination
- GSE308462 ALS molecular subtypes are a combination of cellular, genetic, and pathological features learned by deep multiomics classifiers (post-mortem cortex) 260 samples shares combination
- GSE234519 NSABP B-41: A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer 245 samples shares combination
- GSE225061 Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response 217 samples shares combination
- GSE275078 In vitro drug screening of RAF/MEK/ERK Inhibitors in combination with Autophagy inhibition in the context of two PDA Cell Lines 136 samples shares combination
- GSE286827 4-1BB+ Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy 87 samples shares combination
- GSE315878 Lack of synergy between AR targeted therapies and PARP inhibition in homologous recombination- proficient prostate cancer 70 samples shares combination
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.